Amgen Tells Fed. Circ. Sandoz Would 'Gut' Biosimilar Law
Amgen Inc. fired back Tuesday at rival Sandoz Inc. in Amgen's appeal to the U.S. Federal Circuit over the Affordable Care Act's approval pathway for biosimilars, saying Sandoz's argument against Amgen's...To view the full article, register now.
Already a subscriber? Click here to view full article